TLPH

AcelRx Pharmaceuticals, Inc. focuses on the development and commercialization of therapies for use in medically supervised settings. The company is engaged in creating products that aim to improve patient care and convenience for healthcare providers. Its lead candidate, Niyad® (nafamostat mesylate), is designed to be a regional anticoagulant for use in renal replacement therapy. AcelRx also develops pre-filled syringes for administering ephedrine and phenylephrine in acute care settings.